InvestorsHub Logo
Followers 156
Posts 6362
Boards Moderated 1
Alias Born 08/06/2004

Re: MayoMobile post# 402880

Saturday, 02/11/2023 4:57:11 PM

Saturday, February 11, 2023 4:57:11 PM

Post# of 460262
From Mayo's new article: "When considering published clinically meaningful thresholds for CDR-SB, we can come to the conclusion that Blarcamesine was 125% more efficacious than Lecanemab in CDR-SB when it comes to decreasing patient proximity to clinically meaningful worsening (decline) when considering disease stage. In other words - Blarcamesine-dosed patients at the ~1 year mark demonstrated a far greater distance from what is considered to be meaningful decline than Lecanemab."

https://www.sotcanalytics.com/update-compendium-2023

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News